HYPOGLYCEMIC EFFECT OF METHANOLIC EXTRACT OF BERBERIS ARISTATA DC STEM ON NORMAL AND STREPTOZOTOCIN INDUCED DIABETIC RATS

NITINKUMAR UPWAR*, ROSHAN PATEL, NAHPEED WASEEM1, NAVEEN KUMAR MAHOBIA2

Department of Pharmacognosy, Shree Leuva Patel Trust Pharmacy Mahila College,1 Department of Pharmacology, Shree Leuva Patel Trust Pharmacy Mahila College, Amreli-365601, Gujarat, India *Email: nitinupwar@yahoo.com

Received: 04 Nov 2010, Revised and Accepted: 03 Dec 2010

ABSTRACT

Berberis aristata DC (Berberidaceae) is used in Indian traditional medicine for treating antibacterial, antiperiodic, anti diarrhoeal, ophthalmic, skin diseases and diabetes mellitus. Objective of this study is to induce experimental diabetes mellitus using streptozotocin in normal adult male wistar rats and to study the Antidiabetic activity of methanolic extract of Berberis aristata DC stem (MEBA) by comparison of blood glucose level and total cholesterol (TC), triglyceride (TG), HDL cholesterol (HDLc) levels between normal and diabetic rats. Repeated oral administration of the MEBA (250 & 500 mg/kg) effectively reduced the blood glucose in diabetic rats. (p < 0.05) and also show significant reduction (p < 0.05) in the serum levels of Total cholesterol and Triglycerides and significant increase (p< 0.05) in HDL cholesterol level. Diabetes mellitus is common endocrine disorder. Hypoglycemic agents from natural and synthetic sources are available for treatment of this disease. Indian medicinal plants have been found to be useful to successfully manage diabetes. The stem of Berberis aristata DC was investigated in normal and streptozotocin induced diabetic rats. Significant hypoglycemic activity and hypolipidemic effect was exhibited by the methanolic extract of Berberis aristata DC.

Keywords: Berberis aristata DC, Streptozotocin, Hypoglycemic, Hypolipidemic effect.

INTRODUCTION

Diabetes mellitus is a heterogeneous metabolic disorder old as mankind and its incidence considered to be high (4-5%) all over world1. The use of medicinal plants for the treatment of diabetes mellitus dates back from the Ebers papyrus of about 1550 BC. A multitude of herbs spices and other plant materials have been described for the treatment of diabetes throughout the world2. The medicinal plants might provide a useful source of new oral hypoglycemic compounds for development of pharmaceutical entities or as a dietary adjunct to existing therapies3. Few of the plants used for the treatment of diabetes have received scientific or medicinal scrutiny and even the WHO expert committee on diabetes recommends that this area warrant further attention1.

Berberis aristata DC (Berberidaceae) commonly called as ‘Daruhaldi’ in Hindi is indigenous to India. It is an erect spinous shrub, often found in small patches on the hill slopes. In India mainly found wild in sub –Himalayan tract1. The stem nearly cylindrical, surface rough and colour yellow4. The stem is used for diaphoretic, laxative and in skin diseases5. The Phytochemical examination of methanolic extract of Berberis aristata DC stem was performed by standard methods6.

There are no available reports on pharmacological action of Berberis aristata DC stem till date, therefore, the effect of methanolic extract of Berberis aristata DC stem on blood glucose in normal and streptozotocin induced diabetic rats has been investigated.

MATERIALS AND METHODS

Plant material

The Stem of Berberis aristata DC were purchased from Sanjivani Medicinal plant supplier, Nadiad, Gujarat, Authenticated by Dr. A. S. Reddy, Taxonomist, Bissience Department, Sardar Patel University. Vallabh Vidyanagar, Gujarat, India.

Preparation of extracts

The Stem of Berberis aristata DC were dried in sun and made coarse powder. It was then passed through the 42 mesh sieve. A weighted quantity (200 gm) of the powder was subjected to continuous hot extraction in Soxhlet Apparatus exhaustively. The extract was evaporated under pressure using rotary evaporator until all solvent has been removed to give an extract sample. Percentage yield of methanol extract was 4.2% w/w.

Animals

Male Albino Wistar rats of body weight 250 to 300 gm were selected for all the experiments. Animals were kept in our animal house at an ambient temperature of 25 °C and 45-55% relative humidity with a12 h dark: 12h light cycle. Animal were fed pellet diet (Pranav Agro industries, Vadodara, Gujarat) and water ad libitum. The experiments on animal were conducted in accordance with the international accepted principles for laboratory animal use and the experimental protocols duly approved by the institutional Ethical Committee (Reg. No. IAEC/365/01/ab/CPCSEA).

Phytochemical screening

The Phytochemical examination of methanolic extract of Berberis aristata DC stem was performed by standard methods6.

Acute toxicity study

Acute toxicity study of methanolic extract of Berberis aristata DC stem was determined as per the OECD guideline No. 423 (Acute Toxic Class Method). It was observed that test extract was not lethal to the rats even at 2500 mg/kg dose. Hence, 1/10th (250 mg/kg) and 1/5th (500 mg/kg) of this dose were selected for further study10.

Induction of experimental diabetes

A freshly prepared Streptozotocin (SISCO Research Laboratories Pvt. Ltd, India) 45 mg/kg of body weight in 0.1M Citrate buffer PH 4.5 was injected intraperitoneally to overnight fasted rats11. Hyperglycaemia was confirmed by the elevated blood glucose level determined at 48 hr after the dose. Animal that exhibited glycosuria after 48h was tested by urine test strips (Uristix, Bayer diagnostics Ltd, India) were considered as diabetic.

Experimental design

Hypoglycemic activity in normal rats

Initial testing is carried with the different doses of extract in healthy male rats fasted overnight.

The animals were divided into four groups and each group consisted of 6 rats.

1. Normal control (untreated rats)
2. Normal rats treated with Berberis aristata DC extract (250 mg/kg body weight)

3. Normal rats treated with Berberis aristata DC extract (500 mg/kg body weight)

4. Normal rats treated with Glibenclamide (0.25 mg/kg of body weight)

Hypoglycemic activity in diabetic rats

Eight week after injection of streptozotocin the rats were checked for fasting blood glucose levels. The animal showing fasting blood glucose more than 200 mg/dl were considered as diabetic.

The animals were divided into four groups and each group consisted of 6 rats.

1. Diabetic control (untreated rats)

2. Diabetic rats treated with Berberis aristata DC extract (250 mg/kg body weight)

3. Diabetic rats treated with Berberis aristata DC extract (500 mg/kg body weight)

4. Diabetic rats treated with Glibenclamide (0.25 mg/kg of body weight)

Blood collection and serum separation

The blood sample were collected from 8 h fasted animals from the retro-orbital plexus in capillary tubes. The blood sample were collected from 8 h fasted animals from the retro-orbital plexus in capillary tubes (Micro Hemocrit capillary, Upwar et al., Int J Pharm Pharm Sci, Vol 3, Issue1, 222-224). The blood sample was separated within 30 min. after collection using centrifuge at 2000 rpm for 2 min. for estimation of Glucose and Lipid profile.

Estimation of blood glucose and serum lipid profile

It was estimated by glucose oxidase-peroxidase (GOD-POD) method; total cholesterol (TC), Triglyceride (TG) and HDL cholesterol (HDLc) were estimated by enzymatic methods by using diagnostic kit (Beacon diagnostic Ltd. India).

Statistical analysis

All the data reported are expressed as mean ±S.E.M. Statistical analysis was performed by using one-way ANOVA followed by Turkey’s multiple tests using 2.0 version of computer software. The values were considered statistically significant when P value <0.05 compared to respective control.

RESULTS AND DISCUSSION

Phytochemical Screening

The results of preliminary Phytochemical screening of the methanolic extract of Berberis aristata DC revealed that presence of alkaloids, glycosides, carbohydrates, bitter principles and saponins.

Determination of blood glucose level (BGL) of normal rat

In normal animals significant reduction in blood glucose level at day 12 was observed as compare to normal control (p<0.05).

<table>
<thead>
<tr>
<th>Groups</th>
<th>Drugs</th>
<th>Dose</th>
<th>Blood glucose concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Day 0</td>
<td>Day 12</td>
</tr>
<tr>
<td>Group I</td>
<td>Normal Control</td>
<td>2% Tween80 w/v soln</td>
<td>72.5±0.2</td>
</tr>
<tr>
<td>Group II</td>
<td>Normal Control + MEBA</td>
<td>250mg/kg</td>
<td>72.0±0.4</td>
</tr>
<tr>
<td>Group III</td>
<td>Normal Control + Glibenclamide</td>
<td>50mg/kg</td>
<td>72.5±0.5</td>
</tr>
<tr>
<td>Group IV</td>
<td>Normal Control + Standard Glibenclamide</td>
<td>0.25mg/kg</td>
<td>72.6±0.4</td>
</tr>
</tbody>
</table>

Table 1: Effect of MEBA on normal rats blood glucose level (BGL)

Each value represents mean ±S.E.M. n=6.

*Represent statistical significance vs. control (p<0.05).

One-way ANOVA followed by Tukey’s multiple test.

Determination of blood glucose level (BGL) and lipid profile of diabetic rats.

There were observable changes in blood glucose level (BGL) and lipid profile of treated and untreated rats. Treatment of diabetic rats with the methanolic extract of Berberis aristata DC and Glibenclamide significantly decreased the BGL compared to untreated diabetic rats (p<0.05). Dose dependent reduction (p<0.05) in BGL, TC and TG also increase in HDLc level (p<0.05) was observed in streptozotocin induced diabetic rats treated with methanol extract of Berberis aristata DC.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Drugs</th>
<th>Dose</th>
<th>Blood glucose concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Day 0</td>
<td>Day 12</td>
</tr>
<tr>
<td>Group I</td>
<td>Diabetic Control</td>
<td>2% Tween80 w/v soln</td>
<td>210.1±1.6</td>
</tr>
<tr>
<td>Group II</td>
<td>Diabetic Control + MEBA</td>
<td>250mg/kg</td>
<td>198.2±2.4</td>
</tr>
<tr>
<td>Group III</td>
<td>Diabetic Control + Glibenclamide</td>
<td>500mg/kg</td>
<td>206.3±2.8</td>
</tr>
</tbody>
</table>

Table 2: Effect of MEBA on diabetic rats blood glucose level (BGL) after a prolonged treatment

Each value represents mean ±S.E.M. n=6.

*Represent statistical significance vs. control (p<0.05).

One-way ANOVA followed by Tukey’s multiple test.

Table 3: Effect of MEBA on serum cholesterol levels of streptozotocin induced diabetic rats after a prolonged treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Drugs</th>
<th>Dose</th>
<th>Total</th>
<th>Triglycerides</th>
<th>HDL Cholesterol</th>
<th>Cholesterol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group I</td>
<td>Normal Control</td>
<td>2% Tween80 w/v soln</td>
<td>58.9±0.7</td>
<td>91.1±0.9</td>
<td>54.6±0.4</td>
<td></td>
</tr>
<tr>
<td>Group II</td>
<td>Diabetic Control</td>
<td>2% Tween80 w/v soln</td>
<td>121.0±1.0</td>
<td>178.7±1.2</td>
<td>34.7±0.4</td>
<td></td>
</tr>
<tr>
<td>Group III</td>
<td>Diabetic Control + MEBA</td>
<td>250mg/kg</td>
<td>102.6±0.9ab</td>
<td>87.4±0.9ab</td>
<td>55.9±0.5a</td>
<td></td>
</tr>
<tr>
<td>Group IV</td>
<td>Diabetic control + Glibenclamide</td>
<td>500mg/kg</td>
<td>66.4±0.6ab</td>
<td>87.4±0.9ab</td>
<td>55.9±0.5a</td>
<td></td>
</tr>
<tr>
<td>Group V</td>
<td>Diabetic control + Standard Glibenclamide</td>
<td>0.25mg/kg</td>
<td>75.8±0.9b</td>
<td>90.3±1.56b</td>
<td>53.1±0.6b</td>
<td></td>
</tr>
</tbody>
</table>

Each value represents mean ±S.E.M. n=6.

*a*Represent statistical significance vs. control (p<0.05).

*b*Represent statistical significance vs. normal (p<0.05).

One-way ANOVA followed by Tukey’s multiple test.
DISCUSSION AND CONCLUSION

According to Ayurvedic pharmacopeia of India Berberis aristata DC is used in diabetes. Diabetes mellitus is one of the most common chronic diseases and is associated with hyperlipidemia and co-morbidities such as obesity and hypertension. Hyperlipidemia is a metabolic complication of both clinical and experimental diabetes. In order to establish scientific basis for the utility of this plant in the treatment of diabetes, it was decided to evaluate the hypoglycemic activity of methanolic extract of Berberis aristata DC on normal and diabetic rat by giving multiple doses in experimental design. The presence of alkaloids, glycosides, carbohydrates, bitter principles and Saponins has been implicated in the Antidiabetic activities of many plants.

Previous studies suggested that hyperglycemia and hyperlipidemia are the common characteristics of streptozotocin induced diabetes mellitus in experimental rats. The maximum reduction in serum glucose levels was seen in methanolic extract of Berberis aristata DC at the dose of 500 mg/kg (Table 2) hence, we could say that methanolic extract of Berberis aristata DC had a beneficial effect on carbohydrate metabolism in diabetic rats.

In this study, we have also observed an increase in the concentration of TC and TG in streptozotocin induced diabetic rats. Hyperlipidemia is a recognized consequence of diabetes mellitus. Diabetes induced hyperlipidemia is attributable to excess mobilization of fat from the adipose tissue due to the under utilization of the glucose. Regarding the mechanism of action MEBA may enhance activity of enzymes involved in bile acid synthesis and its excretion and this may have decreased in serum cholesterol and triglycerides. Most of the hypolipidemic drugs do not decrease serum TG level, but MEBA lowered it significantly since under diabetic condition, insulin activates the enzyme lipoprotein lipase and hydrolysis the triglycerides and also MEBA reduces the serum TG of streptozotocin induced diabetic rats and may prevent the progression of CHD. The total lipid profile in serum (total cholesterol, triglycerides) of the streptozotocin induced diabetes rats treated with MEBA (250 or 500 mg/kg) showed significant (p<0.05) reduction, and improve the level of HDL cholesterol as compared to diabetic control rats (Table 3).

The strong antihyperglycemic effect of methanolic extract of Berberis aristata DC stem could indirectly be related to beneficial action against the abnormal high concentration of serum lipids observed in diabetes rats.

REFERENCE